Based on the leading CellRapeuticsTM CAR technology platform, Creative Biolabs has optimized the CAR design and construction services, especially for CAR-T therapy and CAR-NK therapy.
New York, USA - July 3, 2020 - The ability of the body's immune cells to target and eliminate infectious organisms and foreign invaders has been studied for decades. In this field, CAR (chimeric antigen receptor)-expressing T cell therapy and natural killer (NK) cell therapy have generated a lot of excitement and investment in recent years due to the unprecedented clinical results.
Empowered by leading technology and years of experience in biomedical science, Creative Biolabs has executed every strategy to serve comprehensive CAR design and construction services for clients on a worldwide scale.
• CAR-T Gene Packaging & Delivery
The novel immunotherapy, especially the CAR-T therapy, is under rapid development for its unique advantages over conventional cancer treatments. Since the successful manufacture of CAR-T cells is largely dependent on T cell receptor gene transfer, genetic modification of T lymphocytes is one of the most critical steps to generate superior CAR-T cells. To genetically modify T cells with designed CAR, scientists at Creative Biolabs are skillful in adopting various methods to transfect CAR construction into T cells.
Electroporation, retroviral transfection and lentiviral transfection are all available for different applications. Electroporation can be applied for the genetic modification of diverse cell types based on the transient disruption of cell membrane by exposure to an electric field. Retroviral (simple retrovirus, γ-retrovirus, MLV) transfection enables the integration of artificial genes into the host genome in a stable status. Lentiviral (complex retrovirus) transfection, although time-consuming and expensive, performs more powerful on gene integration.
As a new member of CAR Cells' family that can be applied in immunological researches and clinical trials, CAR-NK cells show great potential in clinical application for its higher efficiency with lower toxicity. As an advanced technology service provider, Creative Biolabs supplies high quality CellRapeutics™ CAR-Natural killer (NK) cell construction service for different cancer research purposes tailored according to special needs of clients.
"Based on the established CellRapeutics™ Chimeric Antigen Receptor technology platform, we have successfully developed CAR-NK cells and evaluated their anti-tumor effect and potential safety profile in animal cancer models, which may support your preclinical trial researches," introduced by a senior scientist at Creative Biolabs.
Despite the classical route of CARs, Creative Biolabs also focuses on more special CARs that undergo intensive research recently, such as TanCAR, 7 × 19 CAR, Compound CAR (cCAR), γδ CAR-T, CAR-Macrophage, CAR-NK cells, etc. With one of the world's largest collection of CAR products of different generations targeting various biomarkers, Creative Biolabs will continue to innovate the next generation CAR technologies to achieve even greater results.
Further information can be reached at www.creative-biolabs.com/car-t.
About Creative Biolabs
With more than 15 years' history, Creative Biolabs has talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, Creative Biolabs is the established leading expert in TCR and CAR T&NK cell immune therapy development, offering the one-stop custom services that cover the entire new drug development pipeline.